Dermavant's phase 3 trials of tapinarof – PSOARING 1 and 2 – showed that around 40% of patients responded to treatment with clear or almost clear skin at 12 weeks, compared to 6% of a placebo ...

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.

Roivant group company Dermavant has made the transition to a commercial-stage company after getting FDA approval for Vtama, a drug for psoriasis that it claims could be a game-changer in the ...

Organon (NYSE:OGN) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. JP Morgan does ...